Correlation of Clinical Risk Factors with Diffusion-Weighted Magnetic Resonance Images in Prostate Cancer Patients Treated with Definitive Radiotherapy by Erbay, Gurcan et al.
88 UHOD  Number: 2   Volume: 25   Year: 2015
ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI International Journal of Hematology and OncologyARTICLE
doi: 10.4999/uhod.15813
Correlation of Clinical Risk Factors with 
Diffusion-Weighted Magnetic Resonance Images 
in Prostate Cancer Patients Treated 
with Definitive Radiotherapy
Gurcan ERBAY1, Cem ONAL2, Ozan C. GULER2, Elif KARADELI1, Zafer KOC1
1 Baskent University Faculty of Medicine, Department of Radiology, Ankara 
2 Baskent University Faculty of Medicine, Adana Research and Treatment Centre, Department of Radiation Oncology, 
Adana, TURKEY
ABSTRACT
This study is aimed to correlate apparent diffusion coefficient (ADC) values and clinical T-stage, serum PSA, pathology Gleason 
scores. We also further analyzed whether ADC values could be used to appropriately define the risk groups. 135 biopsy-proven, 
radiotherapy-(RT)-treated, prostate cancer patients who underwent pre-RT DW-MRI and standard T2W pelvic MRI were included. 
ADC and normalized ADC (nADC) values were calculated from DW-MRI delivered a median 8.1 weeks after prostate biopsy. ADC 
values were correlated with clinical risk factor values by using Pearson correlation test. ADCs in low-, intermediate-, and high-risk 
patients were 0.873±0.122X10–3 mm2/s, 0.763±0.124X10–3 mm2/s, and 0.701±0.132X10–3 mm2/s (p= 0.001), respectively. Patients 
with preRT PSA <10 ng/mL had significantly higher ADCs than patients with preRT PSA 10–20 ng/mL (p= 0.02) or >20 ng/mL (p< 
0.001). Mean ADC for patients with Gleason score <7 was significantly higher than patients scoring 7 (p= 0.001) or >7 (p < 0.001). 
Clinical stage <T2b patients had significantly higher ADC values versus stage T2b (p=0.001) and T2b tumors (p< 0.001). ADC dem-
onstrated stronger correlation with NCCN risk groups (R=–0.510; p< 0.001). All clinical factors except Gleason score had moderate 
inverse correlation with nADC. Best nADC correlation occurred with NCCN risk groups (R=-0.461; p< 0.001). ADCs measured by 
DW-MRI are noninvasive prognostic markers of clinical parameters and risk for prostate cancer in RT candidates.
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ÖZET
Definitif Radyoterapi ile Tedavi Edilen Prostat Kanserli Hastalarda Klinik Risk Faktörleri ve Difüzyon Ağırlıklı Manyetik 
Rezonans Görüntülerinin İlişkisi
Bu çalışmanın amacı klinik T evresi, serum prostat spesifik anijen (PSA) ve patolojik Gleason skoru ile apparent diffusion coef-
ficient (ADC) değerlerinin ilişkisini araştırmak. Ayrıca ADC değerlerinin risk gruplarının tanımlanması için uygun olup olmayacağını 
analiz edilmiştir. Definitif radyoterapi (RT) ile tedavi edilen, tedavi öncesi DA-MRG ve standart T2 ağırlıklı MRG’si olan 135 prostat 
kanserli hasta çalışmaya dahil edildi. Prostat biyopsisinden medyan 8.1 hafta sonra çekilen DA-MRG’ lerden ADC ve normalize 
edilmiş ADC (nADC) değerleri ölçüldü. ADC değerleri ve klinik risk faktörleri arasındaki ilişkiyi araştırmak için Pearson korelasyon 
testi kullanıldı. Düşük, orta ve yüksek risk hastalarda ADC değerleri sırası ile 0.873±0.122×10–3 mm2/s, 0.763±0.124×10–3 mm2/s 
ve 0.701±0.132×10–3 mm2/s (p = 0.001) idi. RT öncesi PSA değerleri <10 ng/mL olan hastalar, RT öncesi PSA değerleri 10-20 ng/
mL (p= 0.02) veya >20 ng/mL (p< 0.001) olan hastalara göre istatistiksel olarak anlamı derecede yüksek ADC değerlerine sahipti. 
Gleason Skoru <7 olan hastalar için ortalama ADC skoru, gleason 7 (p = 0.001)  veya >7 (p < 0.001) olanlara göre anlamlı derecede 
yüksekti. Klinik evre <T2b olan hastaların ADC değerleri, evre 2b (p= 0.001) ve >2b (p < 0.001) hastalara göre anlamlı derecede daha 
yüksekti. ADC değerleri National Compheresive Cancer Network (NCCN) risk grupları ile kuvvetli bir korelasyon gösterdi(R=–0.510; 
p< 0.001). Gleason skoru hariç tüm klinik faktörler nADC değeri ile ılımlı ters bir korelasyon içindeydi. nADC’ nin en iyi korelasyonu 
NCCN risk grupları ileydi. (R=–0.461; p< 0.001). DA-MRG ile ölçülen ADC değerleri, RT planlanan prostat kanserli hastalarda önemli 
bir non invaziv prognostik belirteç olarak değerlendirilebilir. 
Anahtar Kelimeler: Apparent difüzyon katsayısı, Difüzyon ağırlıklı MRG, Prognostik faktör, Prostat kanseri, Risk faktörleri
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INTRODUCTION
Prostate cancer is mostly an indolent tumor with 
slow disease progression. However one of six men 
had prostate cancer, but only one of 36 patients 
died with disease. Treatment strategies include 
watchful waiting, radical prostatectomy, or ra-
diotherapy (RT) with or without hormonotherapy, 
depending on disease stage and risk factors.1-3 The 
challenge of managing localized prostate cancer is 
to distinguish patients who may benefit from radi-
cal treatment from patients who do not need any 
intervention. Furthermore, in patients treated with 
RT, treatment strategies depend on clinical param-
eters and, notably, risk groups. 
Currently, serum prostate-specific antigen (PSA), 
clinical T stage, and Gleason scoring are used for 
defining prostate cancer risk.4,5 These risk factors 
have been used to predict the biochemical relapse 
after surgery or RT, and these parameters are also 
used to make treatment choices. Additionally, PSA 
doubling-time and PSA density are used to predict 
disease outcome, but they are nonspecific in de-
termining diseases prognosis.6,7 To predict tumor 
biological behavior, histological evaluation of the 
prostate is required. However, histological evalu-
ation involves invasive biopsy procedure(s) and 
is subject to sampling error. Furthermore, histo-
pathological findings of prostatectomy and biopsy 
specimens do not always accurately reflect actual 
disease status.8,9 There may be discordance be-
tween clinical and pathological staging, and Glea-
son scores of biopsy and prostatectomy specimens 
may vary. For this reason, a thorough evaluation 
of entire prostate is essential before performing 
definitive RT, in which histopathological evalua-
tion is based on prostate biopsy only, and staging is 
performed with clinical and radiological findings. 
Non-invasive methods to evaluate the entire pros-
tate and the tumor biology before performing RT 
may be a promising alternative. Moreover, this ap-
proach would allow optimized treatment delivery 
to adequately stratified patient risk groups. 
 The best method of imaging prostate cancer is en-
dorectal T2-weighted magnetic resonance imaging 
(MRI), which has 60-82% sensitivity and 55-70% 
specificity for detecting cancer.10-12 Additionally, 
recent studies have aimed to determine the value of 
MR correlates of cellular density, metabolite con-
centration, and tumor vascularization for predict-
ing tumor aggressiveness.13-16 Diffusion-weighted 
MRI (DW-MRI) is advantageous in tumor locali-
zation.17-19 DW-MRI may also provide qualitative 
information regarding the pathophysiological char-
acter of prostate cancer.18,20,21 DW-MRI is sensitive 
to the microscopic motion of water molecules and 
allows biological characterization of tissues based 
on their water-diffusion properties. The degree of 
diffusion is quantified as the apparent diffusion co-
efficient (ADC).
Few clinical studies involving limited patient num-
bers have evaluated the potential value of pre-pros-
tatectomy DW-MRI as a non-invasive marker of 
disease aggressiveness.22,23 This study assessed the 
potential importance of ADC values obtained from 
DW-MRI in prostate cancer patients treated with 
definitive RT. Additionally; we analyzed the cor-
relation between ADC values and clinical T-stage, 
serum PSA levels, and Gleason scores. We further 
analyzed whether ADC values could be used to ap-
propriately define the risk groups.
PATIENTS AND METHODS
Study Design and Patient Population
This retrospective study was approved by Baskent 
University Institutional Review Board (Project No 
#KA13/146) and was supported by the Baskent 
University Research Fund. The requirement for 
receipt of written informed consent was waived 
due to the retrospective nature of this study and 
because all patient-identifying information was an-
onymized. All study protocols adhered to the tenets 
of the Declaration of Helsinki. We reviewed the re-
cords of 135 patients with biopsy-proven prostate 
cancer at the Baskent University Faculty of Medi-
cine who were treated with curative intent using 
definitive RT between January 2012 and August 
2013 and who had undergone both DW-MRI and 
standard T2W pelvic MRI before RT. 
Patients were stratified into three risk groups ac-
cording to the National Comprehensive Cancer 
Network (NCCN) guidelines.24 The low-risk group 
contained patients with T1-T2a tumor, Gleason 
score <7, and PSA<10 ng/mL; intermediate-risk 
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patients were T2b tumor, Gleason score= 7, and 
PSA 10-20 ng/mL; and high-risk patients were 
≥T3a tumor, Gleason score >7, and PSA >20 ng/
mL. Pre-RT MRI scans were performed a median 
8.1 weeks (range 4.3-34.1 weeks) after initial pros-
tate biopsy and cancer diagnosis.
Magnetic Resonance Imaging 
For all patients, T2W, fat-saturated T2W, DWI, 
and Dynamic Contrast Imaging- (DCE)-MRI exam 
were performed using a 1.5 T Siemens Avanto® 
MR scanner used as an 8-element, phased-array 
coil during the scans, without an endorectal coil. 
T2W images were acquired with a fast spin-echo 
sequence: repetition time/echo time (TR/TE)= 
5480/55 ms, acquisition matrix 224×320, field of 
view (FOV)= 220 cm, slice thickness 4 mm, and 
intersection gap 1.6 mm. Fat-saturation turbo spin 
echo sequence imaging parameters were: TR/
TE= 5480/55 ms, echo train length= 40, acquisi-
tion matrix 224×320, FOV= 220 cm, slice thick-
ness=1.6 mm. DW-MRI scans were performed 
using a multi-slice, single-shot, spin-echo, planar 
imaging (SE-EPI) sequence (FOV= 365 cm, slice 
thickness= 4mm, EPI-factor= 192, intersection 
gap= 0 mm, TR/TE= 4400/83 ms, acquisition ma-
trix= 192×100, 4 averages, sense factor= 2 in the 
anterior-posterior direction. The b-values of 0, 200, 
600, and 1000 s/mm² were used to calculate ADC. 
The ADC maps were generated automatically us-
ing multi-exponential data fitting with manufac-
turer’s software (syngo.via; Siemens Healthcare, 
Erlangen, Germany). The DCE-MRI protocol 
consisted of a three-dimensional, spoiled-gradient 
echo sequence (3 mm section thickness, TR/TE= 
6.7/3.14 ms, flip angle 100, FOV= 200 cm, acquisi-
tion matrix= 154×256. For DCE imaging, a dose 
of 0.1 mL/kg gadoterate meglumine (Dotarem®; 
Guerbet Group, LLC., Villepinte, France) was in-
jected at 2mL/s, followed by a saline flush.
Data Analysis
Prostate cancer localization was determined by 
consensus of the two experienced genitourinary 
radiologists (≥20-years experience) based on a 
comparison of digital rectal examination findings, 
pathologic biopsy results with four-quadrate and 
12 core biopsy, and the presence of focal low-sig-
nal-intensity areas in the peripheral and/or transi-
tion zones on ADC maps, with using T2W. ADCs 
were determined and maps created using Siemens 
workstation software syngo.via. Diagnostic crite-
ria of prostate cancer in MRI findings were: fo-
cal area(s) revealing low signal intensity on T2W 
images and focal lesion restriction on ADC maps, 
Figure 1. Axial apparent diffusion coefficient map of a corresponding patient demonstrating prostate tumor at left periheral zone. 
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early contrast enhancement with fast washout, and 
high blood vessel permeability on dynamic con-
trast-enhanced images.25,26 Additionally, prostate 
tumors were seen as hyperintense lesions with high 
b-values. 
First, both hyperintense lesions at high b-values 
(especially b= 800 or b= 1000) and lesion with 
diffusion restriction on ADC maps were, when co-
localized in the same area, determined to be focal 
prostatic cancer lesions (Figure 1). Before RT, re-
gions of interest (ROIs) of the tumors in the periph-
eral and/or transition zones were drawn on ADC 
maps to include as much of the tumor as possible, 
calculations were performed twice in the same site, 
and the average of these two values was calculated. 
If a tumor was located in several ADC map im-
aging slices, ADC values were measured on both 
the biggest and the most homogenous regions of 
the same slice. When the ROIs were drawn, great 
care was taken to exclude both the neurovascular 
bundle and the urethra to reduce ADC calculation 
error. For measuring ADC values in the peripheral 
and/or transition zones of benign tissue, ROIs at 
the contralateral side of the tumor were selected. 
Additionally, the normalized ADC (nADC) was 
calculated as the ratio of tumor ADC to normal 
prostate tissue ADC.
Statistical Analysis
Statistical analyses were performed using SPSS 
software version 20 (SPSS Inc./IBM, Chicago, 
IL). Clinical risk factors including Gleason score, 
clinical T-stage, and serum PSA level were cate-
gorized into three groups. A paired Student t-test 
and an independent samples t-test with Bonfer-
roni correction were used to assess differences 
between groups. Pearson correlation analysis was 
performed between ADCs, nADCs, and clinical 
risk factor values. Receiver operating character-
istic (ROC) analysis was performed to assess the 
power of tumor ADC and nADC in discriminating 
between low-, intermediate-, and high-risk groups 
and a cut-off value for this parameter was deter-
mined. A p value of <0.05 was considered indica-
tive of statistically significant differences.
RESULTS
Patient characteristics are summarized in Table 1. 
Almost half of the patients had clinical stage T1c 
tumors or Gleason score 3+3 tumors. Again almost 
one-third of patients were stratified into the low-
risk group, while the remaining two-thirds of pa-
tients were in the intermediate- or high-risk group. 
The overall mean and median serum PSA levels 
were 23.3±8.0 ng/mL and 12.6 ng/mL (range 1.6–
119.6 ng/mL), respectively. 
ADC Measurements
The mean tumor ADC and nADC values were 
(0.773±0.141) ×10−3 mm2/s and (0.581±0.122)×10−3 
mm2/s, respectively. The ADC values in the cen-
tral and peripheral normal prostate tissue were 
(1.321±0.156)×10−3 mm2/s and (1.338±0.152)×10−3 
mm2/s, respectively.
Correlation with Serum PSA
The mean ADC values for PSA groups <10 
ng/mL, 10-20 ng/mL and >20 ng/mL were 
(0.836±0.122)×10−3 mm2/s, (0.751±0.130)×10−3 
mm2/s, and (0.690±0.141)×10−3 mm2/s, respec-
tively (Figure 2A). Patients with low preRT PSA 
levels <10 ng/mL had significantly higher ADC 
Table 1. Patient characteristics
Characteristics No of patients Percent (%)
Age, median (range), yrs  68 (52 – 84) 
Stage  
  T1c 66 49
  T2a 8 6
  T2b 26 20
  T2c 7 5
  T3a 6 4
  T3b 22 16
Gleason score  
  3+3 72 53
  3+4 25 19
  4+3 20 15
  4+4 6 4
  4+5 10 7
  5+5 2 2
Risk groups  
  Low 41 30
  Intermediate 34 25
  High 60 45
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values compared to patients with preRT PSA 10-20 
ng/mL (p= 0.02), and PSA >20 ng/mL (p < 0.001). 
However there was no significant difference be-
tween ADC values of patients with intermediate 
PSA 10–20 ng/mL and PSA >20 ng/mL (p= 0.2) 
levels.
Correlation with Tumor Gleason Scores
The mean ADC for patients with Gleason scores 
<7 (0.829±0.119×10−3/mm2/s) was significant-
ly higher than in patients with Gleason score 7 
(0.720±0.135×10−3 mm2/s; p= 0.001) and pa-
tients with Gleason score >7 (0.624±0.109×10−3 
mm2/s; p< 0.001) (Figure 2B). However, the dif-
ference between Gleason score 7 and Gleason 
score >7 approached statistical significance (p= 
0.08).  
Correlation with Tumor Stage
Patients with clinical stage <T2b tumors had sig-
nificantly higher ADC values (0.832±0.117×10−3 
mm2/s) compared to patients with stage-T2b tu-
mors (0.708±0.135×10−3 mm2/s; p= 0.001), and 
stages >T2b tumors (0.673±0.127×10−3 mm2/s; p 
< 0.001) (Figure 2C). However there was no sig-
nificant difference between ADC values of patients 
with clinical stage T2b tumor and >T2b tumors (p= 
0.6).
Correlation with NCCN Risk Groups
 We stratified patients into risk groups based on 
composites of Gleason score, serum PSA lev-
els, and tumor stage. The ADC values in low-, 
intermediate-, and high-risk patient groups were 
(0.873±0.122)×10−3 mm2/s, (0.763±0.124)×10−3 
mm2/s, and (0.701±0.132)×10−3 mm2/s, respective-
ly (Figure 2D). The differences between all paired 
risk group comparisons were significant.
	   	  
	   	  
Figure 2. ADC values measured in diffusion-weighted magnetic resonance imaging before radiotherapy according to (A) PSA levels, 
(B) Gleason scores (C) clinical T-stage, and (D) risk groups.
A
D
C
 m
ea
n 
(x
10
–3
/m
m
2 /
s)
1.000
.800
.600
.400
.200       
A
D
C
 m
ea
n 
(x
10
–3
/m
m
2 /
s)
1.200
1.000
.800
.600
.400
A
D
C
 m
ea
n 
(x
10
–3
/m
m
2 /
s)
1.200
1.000
.800
.600
.400
A
D
C
 m
ea
n 
(x
10
–3
/m
m
2 /
s)
1.200
1.000
.800
.600
.400
Low risk                   Intermediate risk                High risk
Risk group
<10                         10-20                             >20
PSA group
<7                                 7                                  >7
Gleason score
<T2b                            T2b                             >T2b
Clinical T stage
A
D
B
C
93UHOD   Number: 2   Volume: 25   Year: 2015
International Journal of Hematology and Oncology
Normalized ADC Measurements 
The mean nADC values for PSA groups <10 ng/
mL, 10-20 ng/mL, and >20 ng/mL were 0.63, 
0.57, and 0.51, respectively (Figure 3A). The only 
significant difference in nADC values existed be-
tween patients with PSA <10 ng/mL versus pa-
tients with PSA >20ng/mL (p= 0.001). The mean 
nADC for patients with Gleason score <7 (0.62) 
was significantly higher than patients with Gleason 
score 7 (0.55; p= 0.04) and patients with Gleason 
score >7 (0.50; p= 0.03) (Figure 3B). However, 
the nADC difference between Gleason score 7 and 
Gleason score >7 groups did not reach statistical 
significance (p= 0.6). Patients with clinical stage 
<T2b tumors had significantly higher nADC val-
ues (0.63) compared to patients with clinical stage 
T2b tumors (0.53; p= 0.04) and stage >T2b tumors 
(0.51; p= 0.001) (Figure 3C). However, there was 
no significant difference between nADC values of 
patients with clinical stage T2b tumors versus >T2b 
tumors (p= 0.9). The nADC values in the low-, in-
termediate-, and high-risk patients were 0.66, 0.58, 
and 0.52, respectively (Figure 3D). The nADC 
differences between low- versus intermediate-risk 
groups (p= 0.04), and low- versus high-risk groups 
(p< 0.001) were significant. No significant differ-
ence in nADCs existed between the intermediate- 
and high-risk groups.
Correlation Between Clinical Factors
Significant and inverse moderate correlations be-
tween all clinical factors and ADCs were observed 
(Table 2). The ADC demonstrated the best correla-
tion with the NCCN risk groups (Pearson=-0.510; 
p< 0.001). All clinical factors except the Gleason 
score were inversely and moderately correlated 
with nADCs. As with the ADC, the best correla-
tion with nADC was observed with the NCCN risk 
groups (Pearson=–0.461; p< 0.001). 
Figure 3. Normalized ADC values measured in diffusion-weighted magnetic resonance imaging before radiotherapy according to (A) 
PSA levels, (B) Gleason scores (C) clinical T-stage, and (D) risk groups.
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ROC analysis
Fig- u r e 4 shows the ROC curve analyzing 
ADC and nADC in discriminating 
the low-risk group with the intermedi-
ate- or high-risk groups. The area under the 
curve was 0.857 (p< 0.001; 95% confidence 
interval: 0.769–0.946) for ADC measure-
ments, and 0.802 (p= 0.001; 95% confidence 
i n - terval: 0.637-0.865) for nADC values. For a 
79% risk-prediction accuracy, an ADC cut-
o f f of 0.802×10−3/mm2/s gave a sensitivity of 
82% and specificity of 78%. Also, for a 68% 
r i s k -
prediction accuracy, a nADC cut-off value of 0.59 
gave a sensitivity of 68% and specificity of 66%.
DISCUSSION
This study demonstrates that ADC values can dis-
tinguish between among the clinical parameters 
and define risk factors that are used when select-
ing RT strategies for treating prostate cancer. In 
low-risk patients, prostate RT is adequate treat-
ment, whereas in intermediate- and high-risk pa-
tients, hormone therapy is delivered concurrently 
with RT. Additionally, negative correlations were 
found between ADC values and clinical param-
eters including serum PSA level, clinical T-stage, 
and Gleason score.
Water diffusion characteristics are substantially 
affected by cellular and structural changes within 
tissues, including cell density, vascularity and mi-
crovascular tortuosity, extracellular fluid viscosity, 
membrane permeability between intra- and extra-
cellular compartments, active transport and flow, 
and directionality of tissue/cellular structures that 
impede water mobility.27 These cellular and struc-
tural differences exist between low- and high-risk 
lesions, and they can be measured non-invasively 
in vivo using DW-MRI, which constructs images 
based on quantifying water molecule diffusion 
within tissues.28
The ADC is a quantitative parameter of the ex-
tent of water molecule diffusion. Due to increased 
cellularity, decreased extracellular space, and ab-
normal microvasculature, tumor ADCs are gener-
ally lower than surrounding normal tissues. Fur-
thermore, ADC values can potentially be used to 
predict tumor aggressiveness.22,29,30 Bae et al.22 
demonstrated that prostate cancer patients with a 
Gleason score ≥4+3, larger tumors (≥16 mm), and 
highly proliferating cancers had significantly low-
er ADC values in 29 patients treated with radical 
prostatectomy. Oto et al.29 found a moderate nega-
tive correlation between Gleason score (r –0.376, 
p= 0.001) and tumor ADC values in 73 prostate 
cancer patients treated with radical prostatectomy. 
In 39 patients treated with radical prostatectomy, 
Thörmer et al.21 found that nADC could be used as 
a valuable surrogate for predicting tumor aggres-
siveness. deSouza et al.23 demonstrated significant 
differences in ADC values between patients at 
low-risk and those with higher-risk localized pros-
tate cancer. We evaluated more patients compared 
to these previous studies, and we demonstrated a 
significant correlation between ADCs and diverse 
clinical parameters and NCCN risk groups. 
Figure 4. Receiver operating characteristic curve analysis in 
risk group prediction according to ADC and nADC.
Table 2. Correlation between ADC, nADC and clinical prognostic parameters
 ADC                                             nADC
Parameter Pearson correlation  p Pearson correlation p
 coefficient  coefficient
PSA -0.443 <0.001 -0431 <0.001
Gleason score -0.496 <0.001 -0.351 <0.001
Clinical T stage -0.501 <0.001 -0.430 <0.001
Risk groups -0.510 <0.001 -0.461 <0.001
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All patients had been treated with definitive RT. 
Therefore, we could not perform a detailed anal-
ysis of histopathological correlations with ADC 
values. In some cases, there may be discordance 
between histopathological findings in biopsy and 
prostatectomy specimens. Previous studies have 
shown significant pathologic upgrading at radical 
prostatectomy, with reported upgrading percent-
ages ranging from 20.3%-54%.15 This potentially 
creates a problem with accurately identifying and 
monitoring patients who are erroneously catego-
rized as having low-risk disease before surgery. 
For defining NCCN risk groups, patients were 
stratified according to Gleason score, serum PSA 
level, and clinical T-stage. Although ADC values 
are known to correlate with tissue structure, the 
NCCN criteria rather than Gleason score were used 
to define risk groups, to reduce the effects of bi-
opsy sampling variability and reflect that our ADC 
values were averaged over the whole tumor ROI. 
Averaging ADCs over the ROI is a limitation, as 
it does not account for ADC differences within the 
tumor itself; therefore, correlation of these differ-
ences with histopathology would be useful. Further 
study of DW-MRI in localized prostate cancer is 
also warranted to assess its correlative utility in 
relation to tumor histopathology and clinical out-
comes.
Although several study evaluated ADCs for deter-
mining tumor aggressiveness, few studies defined 
the cut-off values to predict high-grade cancer 
foci.21-23 Bae et al.22 determined the cut-off ADC 
value of 0.52×10−3 mm2/s as having low- versus 
high-grade tumors. deSouza et al.23 found that 
ADC cut-off values of 1.33×10−3 mm2/s (sensitiv-
ity 89%, specificity 58%) and 1.20×10−3/mm2/s 
(sensitivity 55%, specificity 95%) provided 70% 
of risk prediction. Thörmer et al.21 defined nADC 
values below 0.46 as the threshold for tumors with 
intermediate or high aggressiveness. The ADC cut-
off values may vary between studies because of 
different enrolled patient numbers and varied ADC 
measurement techniques. In our study we evaluat-
ed both ADC and nADC values. We found that for 
70% risk prediction, an ADC cut-off of 0.802×10−3 
mm2/s gave a sensitivity of 82% and specificity of 
78%, and a nADC cut-off value of 0.59 gave a sen-
sitivity of 68% and specificity of 66%. Although 
our ADC and nADC cut-off values were higher 
than previously reported findings, our results may 
be more reliable because we studied larger number 
of patients. 
ADC value measurement has not been standard-
ized yet. In some studies, minimum ADC values 
were correlated with tumor biological aggressive-
ness31,32, whereas other researchers used mean 
ADC values as a surrogate for tumor aggressive-
ness.22,33 Although there is intratumoral heteroge-
neity in prostate cancer, we used the mean ADC 
values. However, to minimize ADC measurement 
error, ADC was measured on much larger tumor 
volumes that previously studied, by averaging 
ADC maps of several imaging slices.
The main limitation of T2W imaging is false posi-
tivity for low-signal intensity lesions, where infec-
tion, inflammation, and fibrosis may mimic the 
tumor. In this study, to diminish false results, the 
radiologists delineating the ROI were aware of the 
tumor localization that was verified with biopsy. 
However, on post-biopsy T2W images, hemor-
rhage has low signal intensity that can mimic the 
tumor and lead to inaccurate measurements.27 In 
previous studies analyzing the importance of ADC 
in prostate cancer patients22,23, the MRI scans were 
delivered before prostate biopsy, which makes the 
result more accurate. We evaluated the patients be-
fore initiation of RT, and MRI scans were all taken 
before RT with biopsy proven prostate cancer. In 
suspected cases, T1W images of the whole pelvis 
were taken at the same time to differentiate hemor-
rhage and minimize artifactual error introduction 
into ADC measurements. 
A major limitation of this study is the lack of cor-
relating tumor ROIs with whole-mount histopa-
thology sections, because all patients in this study 
were treated with definitive RT. In the high-risk 
cohort, all lesions were large and easily discern-
ible on T2W imaging, so the likelihood of error in 
ROI selection is low. In the low-risk cohort, where 
all lesions were verified with biopsy data, the ADC 
values were likely to have been indistinguishable 
from adjacent non-malignant prostate tissue. In 
these cases, the lack of a visually identifiable lesion 
on the ADC map is also an indicator of the low-risk 
nature of the lesion. A more problematic feature is 
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that we used the averaged ADC from the entire 
tumor region, and this was often heterogeneous. 
It may be that the more diffusion-restricted areas 
within the tumor region are ultimately more pre-
dictive of outcome. Also, the absolute cut-off val-
ues for the ADC and nADC have not yet been ap-
propriately defined and standardized, because prior 
studies used different measurement techniques and 
were prone to inter-observer variability. The im-
ages in our study were interpreted by consensus of 
two readers rather than by separate analyses. The 
purpose of this study, however, was not to assess 
ADC diagnostic accuracy for predicting localized 
prostate cancer by DW-MRI but to correlate the 
ADC values with clinical rsik factors using 1.5T 
MRI. Another study limitation was that all patient 
underwent transrectal sonography guided-biopsy 
with pretreatment MR examination, which might 
have had potential effects on subsequent ADC 
measurement due to hemorrhage or inflammatory 
changes in the normal prostate tissue.
In conclusion, DW-MRI offers potential to evalu-
ate prostate cancer patients treated with definitive 
RT, where complete histopathological evaluation 
of the entire prostate is not possible. We found 
that ADC values measured using DW-MRI can 
noninvasively determine clinical parameters and 
risk groups for prostate cancer patients that have 
prognostic significance. However, further work is 
needed to conclusively determine the clinical sig-
nificance of using ACDs to define risk groups and 
to evaluate treatment responses after definitive RT 
for prostate cancer.  
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